Research

The research interest of my group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:

• The molecular mechanisms whereby cancer cells induce changes in the host immune system
• The use of allogeneic stem cell bone marrow transplant to induce a graft versus leukaemia effect
• Identification of the antigenic targets expressed by cancer cells
• Use of agents that will make tumour cells more susceptible to immune cell mediated killing, without impacting on the host immune system

Other Activities

• European Hematology Association (EHA), President 2019-2021
• President-elect 2017-2019
• EHA Governing Board, 2015-
• International workshop for NHL – Chair 2014-
• MRC Molecular and Cellular Medicine Board (MCMB), 2007-2012

Major Funding

• 2017-2022- The London Clinic, Provision of clinical research Fellows in Haematology
• 2016-2019- Janssen Biotech Inc, Targeting PD-LI/PD-1 mediated inbhibitory signaling with BTK inhibitors
• 2016-2019- Wellcome Trust, Understanding the rise of HIV-assoicated Hodgkin Lymphoma despite HAART; the role of immune dysregulation
• 2015-2018- Barts Charity, Understanding the microenvironment in HIV associated Hodgkin Lymphoma, £283,221
• 2014-2019- NCI/NIH Programme Grant – CLL Research Consortium, Understanding the impact of CLL on T cell immune responses, $1,200,000

Recent Publications

Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma. Gribben JG, Palomba ML, Patel AR et al. Blood Adv (2023) (2)
https://www.ncbi.nlm.nih.gov/pubmed/36661331

Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL Gagelmann N, Gribben J, Kröger N (2022) (18)

Educational Needs for Physicians Kröger N, Gribben J, Sánchez-Ortega I (2022) (18)

Evaluating an interactive acceptance and commitment therapy (ACT) workshop delivered to trained therapists working with cancer patients in the United Kingdom: a mixed methods approach Moschopoulou E, Brewin D, Ridge D et al. BMC Cancer (2022) 22(7)

Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications Baptista MJ, Tapia G, Muñoz-Marmol AM et al. Histopathology (2022) 81(7) 826-840

Genomic profiling for clinical decision making in lymphoid neoplasms de Leval L, Alizadeh AA, Bergsagel PL et al. Blood (2022) 140(7) 2193-2227

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL) Ghione P, Palomba ML, Ray MD et al. Blood (2022) 140(10) 4676-4677

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML Rio-Machin A, Bewicke-Copley F, Zheng J et al. Blood (2022) 140(10) 1030-1032

Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation Perrett M, Pickard L, Kumar E et al. Blood (2022) 140(10) 748-749

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study Munir T, Cherrill L-R, Webster N et al. Blood (2022) 140(10) 222-223

Team

Group Leaders in the Centre
Dr Andrejs Braun, Dr Jeff Davies, Dr Gabriella Ficz, Professor Kamil R. Kranc, Dr Sergey Krysov, Dr Rifca Le Dieu, Dr Kevin Rouault-Pierre, Dr John Riches, Dr Bela Wrench

Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove

Biography

I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.

In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.